Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01367366
Other study ID # 201004018R
Secondary ID
Status Recruiting
Phase N/A
First received May 20, 2010
Last updated June 6, 2011
Start date May 2010

Study information

Verified date May 2011
Source National Taiwan University Hospital
Contact Chao-Chi Ho, PhD
Phone 886-972651317
Email ccho1203@gmail.com
Is FDA regulated No
Health authority Taiwan: Department of Health
Study type Observational

Clinical Trial Summary

Lung cancer is the leading cause of death in Taiwan. The outcomes of the disease vary depending on early detection, histologic types and staging. Because the mediastinal involvement including lymph node status is a significant prognostic factor for survival, lymph node biopsy is necessary for clinical staging of some patients. Although fluorodeoxyglucose-positron emission tomography (FDG-PET) is suggested for precise evaluation of mediastinum, tissue proof of PET positive lesions are recommended due to its limited diagnostic specificity for identifying mediastinal metastases. Cervical mediastinoscopy remains the "gold standard" for mediastinal lymph node sampling. However, it is invasive, requires general anesthesia. Another new minimally invasive method of mediastinal biopsy is real-time endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA). The aim of this study is to compare the accuracy of PET and EBUS-TBNA for correct staging of the mediastinum for lung cancer patients.


Description:

Lung cancer ranks among the most commonly occurring malignancies and currently is the leading cause of cancer-related cause worldwide including Taiwan [1, 2]. Although a lot of research focus on the treatment of lung cancer, the prognosis of lung cancer remains dismal and a five year survival ate is less than 15% [3]. Unfortunately, early detection of lung cancer is still a problem. In a tertiary care hospital in Taiwan, only 27.3% of patients could received operation (stage I 15%, stage II 7.5%) [4]. Lymph node staging is also important for evaluation the possibility of operation.

Fluorodeoxyglucose-positron emission tomography (FDP-PET) is now used by oncologist to evaluate lung masses, solitary pulmonary nodules and intrathoracic lymph nodes. As the technique becomes more widespread, it is now used even as a first line imaging investigation. Although PET has a high negative predictive value, it is neither sensitive nor specific to differentiate benign from malignant mediastinal lymph nodes [5, 6]. If PET positive mediastinal lymph nodes are equal to malignant involvement, some patients might be excluded from potentially curative surgery. Several national guideline groups suggest that PET positive lymph nodes should be biopsied if it is likely that the result will alter clinical management [7, 8].

"Cervical mediastinoscopy" has been regarded as the "standard procedure" for sampling mediastinal lymph nodes. However, these techniques require general anesthesia and could not be repeated because of adhesion. Access to hilar nodal stations can be difficult for mediastinoscopy. In recent years, one minimally invasive method endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) was used for biopsy of both hilar and mediastinal lymph nodes [9]. EBUS-TBNA allows the mediastinal lymph nodes to be targeted in the areas accessible to cervical mediastinoscopy, as well as some hilar nodes (lymph node stations 2-4, 7, 10-12)[9] .

Kazuhiro Yasufuku had published the first report of real-time EBUS-TBNA in evaluating mediastinal lymphadenopathy in 2004 [10]. Currently, the main indication of EBUS-TBNA is the mediastinal nodal staging of NSCLC after recent meta-analyses established the comparable sensitivity and specificity of nodal staging by EBUS-TBNA and cervical mediastinoscopy [11]. Efficacy in evaluation of other disease processes such as sarcoidosis and lymphoma has also been established [12].

Although there were several large studies to compare the diagnostic efficacy of mediastinal malignant lymphadenopathy between FDG-PET and EBUS-TBNA, the investigators need to have our own data because of high incidence of TB lymphadenitis in Taiwan, where the diagnostic accuracy of PET may be lower than other countries.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date
Est. primary completion date April 2012
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Age older than 18 years

2. Patient with suspected malignant mediastinal lymphadenopathy

Exclusion Criteria:

1. Age younger than 18 years

2. Bleeding diathesis(INR > 1.4, Platelet count < 10,000/mcl)

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


Intervention

Procedure:
PET and EBUS-TBNA
PET and EBUS-TBNA once, respectively

Locations

Country Name City State
Taiwan National Taiwan University Hospital Taipei

Sponsors (1)

Lead Sponsor Collaborator
National Taiwan University Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Diagnostic value of PET and EBUS-TBNA Thg diagnostic criteria for malignant mediastinal lymphadenopathy is as followed:
EBUS-TBNA: postive cytology or patholoy result of the culprit lymph node
PET: SUVmax >2.5 of the culprit lymph node
The gold standard diagnostic method is surgical biopsy of the culprit lymph node.
The sensitivity,specificity,positive and negative predictive value will be calculated.
1 week No
See also
  Status Clinical Trial Phase
Completed NCT05535439 - Diagnostic Yield & Specimen Adequacy of Flex 19 G vs 22 G EBUS Needle - A Randomized Controlled Trial N/A
Completed NCT04572984 - Transbronchial Mediastinal Cryobiopsy Combined With EBUS-TBNA in the Diagnosis of Mediastinal Lesions N/A
Withdrawn NCT01467635 - EBUS-TBNA Versus EBUS-TBNB N/A
Not yet recruiting NCT02398864 - Accuracy and Safety of Endobronchial Ultrasound (EBUS) in Suspected Non-malignant Mediastinal Lymphadenopathy N/A
Not yet recruiting NCT04200105 - EBUS-TBNA vs Acquire TBNB N/A
Recruiting NCT05374447 - Diagnostic Yield of Intranodal Forceps Biopsies in Mediastinal Adenopathy N/A
Not yet recruiting NCT05110950 - Endobronchial Ultrasound Needle Aspiration With and Without Suction N/A
Recruiting NCT01493739 - EBUS-TBNA for Diagnosis of Mediastinal Lymphadenopathy N/A
Active, not recruiting NCT05077111 - A Comparative Study Between Regional Anesthesia in Thoracoscopes and the Conventional General Anesthesia Phase 4
Completed NCT02689050 - Optical Biopsy for Thoracic Lymph Nodes. N/A
Completed NCT02710565 - Use of EBUS TBNA for Cell Culture as an Aid to Diagnose Lung Cancer and Lymphoma N/A
Completed NCT01734980 - Endobronchial Ultrasound Transbronchial Needle Aspiration Using Needle Suction Versus No Suction N/A
Completed NCT01658280 - Conventional Versus Ultrasound-guided Transbronchial Needle Aspiration for the Diagnosis of Hilar/Mediastinal Lymphadenopathies Phase 4
Recruiting NCT01121432 - Diagnosis of Mediastinal Tuberculous Lymphadenopathy by Endobronchial Ultrasound-guided Transbronchial Needle Aspiration (EBUS-TBNA) N/A
Recruiting NCT05803239 - Study on Transbronchial Ultrasound-guided Cryobiopsy in the Diagnosis of Mediastinal Lymphadenopathy N/A
Recruiting NCT06347939 - Mediastinal EBUS Cryobiopsy Study In Sweden
Completed NCT04306614 - Capillary Versus Suction Needle Aspiration for Endobronchial Ultrasound (EBUS) Biopsies. N/A
Terminated NCT03829618 - Lidocaine Administration During Flexible Bronchoscopy and Endobronchial Ultrasound Phase 3